Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,804 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies.
Wu J, Bloch N, Chang AY, Bhavsar R, Wang Q, Crawford A, DiLillo DJ, Vazzana K, Mohrs K, Dudgeon D, Patel S, Ahmed H, Garg V, Amatulli M, Antao OQ, Yan Y, Wang S, Ramos W, Krueger P, Adler C, Ni M, Wei Y, Guo C, Macdonald L, Huang T, Ullman E, Hermann A, Yancopoulos GD, Murphy AJ, Davis S, Olson WC, Lin JC, Smith E, Zhang T. Wu J, et al. Among authors: lin jc. Cell Rep Med. 2024 Oct 15;5(10):101747. doi: 10.1016/j.xcrm.2024.101747. Epub 2024 Sep 25. Cell Rep Med. 2024. PMID: 39326410 Free PMC article.
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy.
Waite JC, Wang B, Haber L, Hermann A, Ullman E, Ye X, Dudgeon D, Slim R, Ajithdoss DK, Godin SJ, Ramos I, Wu Q, Oswald E, Poon P, Golubov J, Grote D, Stella J, Pawashe A, Finney J, Herlihy E, Ahmed H, Kamat V, Dorvilliers A, Navarro E, Xiao J, Kim J, Yang SN, Warsaw J, Lett C, Canova L, Schulenburg T, Foster R, Krueger P, Garnova E, Rafique A, Babb R, Chen G, Stokes Oristian N, Siao CJ, Daly C, Gurer C, Martin J, Macdonald L, MacDonald D, Poueymirou W, Smith E, Lowy I, Thurston G, Olson W, Lin JC, Sleeman MA, Yancopoulos GD, Murphy AJ, Skokos D. Waite JC, et al. Among authors: lin jc. Sci Transl Med. 2020 Jun 24;12(549):eaba2325. doi: 10.1126/scitranslmed.aba2325. Sci Transl Med. 2020. PMID: 32581132
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning.
Haber L, Olson K, Kelly MP, Crawford A, DiLillo DJ, Tavaré R, Ullman E, Mao S, Canova L, Sineshchekova O, Finney J, Pawashe A, Patel S, McKay R, Rizvi S, Damko E, Chiu D, Vazzana K, Ram P, Mohrs K, D'Orvilliers A, Xiao J, Makonnen S, Hickey C, Arnold C, Giurleo J, Chen YP, Thwaites C, Dudgeon D, Bray K, Rafique A, Huang T, Delfino F, Hermann A, Kirshner JR, Retter MW, Babb R, MacDonald D, Chen G, Olson WC, Thurston G, Davis S, Lin JC, Smith E. Haber L, et al. Among authors: lin jc. Sci Rep. 2021 Jul 13;11(1):14397. doi: 10.1038/s41598-021-93842-0. Sci Rep. 2021. PMID: 34257348 Free PMC article.
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
Crawford A, Haber L, Kelly MP, Vazzana K, Canova L, Ram P, Pawashe A, Finney J, Jalal S, Chiu D, Colleton CA, Garnova E, Makonnen S, Hickey C, Krueger P, DelFino F, Potocky T, Kuhnert J, Godin S, Retter MW, Duramad P, MacDonald D, Olson WC, Fairhurst J, Huang T, Martin J, Lin JC, Smith E, Thurston G, Kirshner JR. Crawford A, et al. Among authors: lin jc. Sci Transl Med. 2019 Jun 19;11(497):eaau7534. doi: 10.1126/scitranslmed.aau7534. Sci Transl Med. 2019. PMID: 31217340
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
Skokos D, Waite JC, Haber L, Crawford A, Hermann A, Ullman E, Slim R, Godin S, Ajithdoss D, Ye X, Wang B, Wu Q, Ramos I, Pawashe A, Canova L, Vazzana K, Ram P, Herlihy E, Ahmed H, Oswald E, Golubov J, Poon P, Havel L, Chiu D, Lazo M, Provoncha K, Yu K, Kim J, Warsaw JJ, Stokes Oristian N, Siao CJ, Dudgeon D, Huang T, Potocky T, Martin J, MacDonald D, Oyejide A, Rafique A, Poueymirou W, Kirshner JR, Smith E, Olson W, Lin J, Thurston G, Sleeman MA, Murphy AJ, Yancopoulos GD. Skokos D, et al. Among authors: lin j. Sci Transl Med. 2020 Jan 8;12(525):eaaw7888. doi: 10.1126/scitranslmed.aaw7888. Sci Transl Med. 2020. PMID: 31915305
CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models.
Wei J, Montalvo-Ortiz W, Yu L, Krasco A, Olson K, Rizvi S, Fiaschi N, Coetzee S, Wang F, Ullman E, Ahmed HS, Herlihy E, Lee K, Havel L, Potocky T, Ebstein S, Frleta D, Khatri A, Godin S, Hamon S, Brouwer-Visser J, Gorenc T, MacDonald D, Hermann A, Chaudhry A, Sirulnik A, Olson W, Lin J, Thurston G, Lowy I, Murphy AJ, Smith E, Jankovic V, Sleeman MA, Skokos D. Wei J, et al. Sci Transl Med. 2022 Nov 9;14(670):eabn1082. doi: 10.1126/scitranslmed.abn1082. Epub 2022 Nov 9. Sci Transl Med. 2022. PMID: 36350988
[No title available]
[No authors listed] [No authors listed] PMID: 37613478
A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants.
Yang Y, Suhasini AN, Jiang Z, Liu N, Rosconi M, Zhang B, Li Y, Dudgeon D, Seong C, Kim S, Rafique A, Huang T, Bhosle S, Krueger P, Ullman E, Olson W, Lin JC, Shen Y, Daly C. Yang Y, et al. Among authors: lin jc. Cancer Res. 2024 Jul 2;84(13):2169-2180. doi: 10.1158/0008-5472.CAN-23-3195. Cancer Res. 2024. PMID: 39082679 Free PMC article.
A novel bispecific antibody platform to direct complement activity for efficient lysis of target cells.
Cruz JW, Damko E, Modi B, Tu N, Meagher K, Voronina V, Gartner H, Ehrlich G, Rafique A, Babb R, Aneja P, Potocky TB, D' Orvilliers A, Coppi A, E SY, Qiu H, Williams CM, Bennett BL, Chen G, Macdonald L, Olson W, Lin JC, Stahl N, Murphy AJ, Kyratsous CA, Prasad BC. Cruz JW, et al. Among authors: lin jc. Sci Rep. 2019 Aug 19;9(1):12031. doi: 10.1038/s41598-019-48461-1. Sci Rep. 2019. PMID: 31427700 Free PMC article.
1,804 results